WO1999043299A3 - Oral formulation for hydrophilic drugs - Google Patents

Oral formulation for hydrophilic drugs Download PDF

Info

Publication number
WO1999043299A3
WO1999043299A3 PCT/US1999/003675 US9903675W WO9943299A3 WO 1999043299 A3 WO1999043299 A3 WO 1999043299A3 US 9903675 W US9903675 W US 9903675W WO 9943299 A3 WO9943299 A3 WO 9943299A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral formulation
hydrophilic drugs
concentrate
pharmaceutical
oral
Prior art date
Application number
PCT/US1999/003675
Other languages
French (fr)
Other versions
WO1999043299A2 (en
Inventor
Lu Mou Ying Fu
John F Bauer
Walter Dziki
Victor E Taylor
Zheng Wang
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to AU28708/99A priority Critical patent/AU2870899A/en
Publication of WO1999043299A2 publication Critical patent/WO1999043299A2/en
Publication of WO1999043299A3 publication Critical patent/WO1999043299A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical composition and concentrate suitable for oral administration comprising a hydrophilic drug solubilized in a lipophilic phase comprising a fatty acid, and water; an oral formulation comprising uniform dispersion of the pharmaceutical concentrate in an aqueous phase optionally comprising a self-emulsifying material; and to a process of making the same.
PCT/US1999/003675 1998-02-26 1999-02-19 Oral formulation for hydrophilic drugs WO1999043299A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU28708/99A AU2870899A (en) 1998-02-26 1999-02-19 Oral formulation for hydrophilic drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3120498A 1998-02-26 1998-02-26
US09/031,204 1998-02-26

Publications (2)

Publication Number Publication Date
WO1999043299A2 WO1999043299A2 (en) 1999-09-02
WO1999043299A3 true WO1999043299A3 (en) 1999-11-04

Family

ID=21858162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003675 WO1999043299A2 (en) 1998-02-26 1999-02-19 Oral formulation for hydrophilic drugs

Country Status (5)

Country Link
AR (1) AR015531A1 (en)
AU (1) AU2870899A (en)
CO (1) CO4970788A1 (en)
WO (1) WO1999043299A2 (en)
ZA (1) ZA991539B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416169C (en) 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
BR0109317A (en) 2000-07-14 2003-06-17 Allergan Inc Compositions containing alpha-2-adrenergic agonist components
ES2385240B1 (en) 2010-07-26 2013-09-23 Gp-Pharm, S.A. CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
CN116270492A (en) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 Leuprolide acetate sustained-release microsphere for injection and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003751A1 (en) * 1991-08-26 1993-03-04 Abbott Laboratories Compositions and methods for the sublingual or buccal administration of therapeutic agents
WO1997006813A1 (en) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide
WO1998005300A2 (en) * 1996-08-07 1998-02-12 Abbott Laboratories Delivery system for pharmaceutical agents encapsulated with oils

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003751A1 (en) * 1991-08-26 1993-03-04 Abbott Laboratories Compositions and methods for the sublingual or buccal administration of therapeutic agents
WO1997006813A1 (en) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide
EP0845265A1 (en) * 1995-08-15 1998-06-03 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide
WO1998005300A2 (en) * 1996-08-07 1998-02-12 Abbott Laboratories Delivery system for pharmaceutical agents encapsulated with oils

Also Published As

Publication number Publication date
CO4970788A1 (en) 2000-11-07
AU2870899A (en) 1999-09-15
AR015531A1 (en) 2001-05-02
WO1999043299A2 (en) 1999-09-02
ZA991539B (en) 1999-08-25

Similar Documents

Publication Publication Date Title
ES2402544T3 (en) Quickly soluble film preparation
CA2337046A1 (en) Sustained release pharmaceutical preparation
IE871584L (en) Sustained release capsule.
WO2001095899A3 (en) Pharmaceutical compositions comprising cannabidiol derivatives
CA2392473A1 (en) Bioadhesive drug delivery system
CA2274773A1 (en) Aqueous therapeutic agents of ibuprofen
AU2001232337A1 (en) Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
WO2001089479A3 (en) Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
NO20005431D0 (en) Gellable pharmaceutical preparations
WO1990003164A3 (en) Pharmaceutical formulations
EP1161956A4 (en) Medicinal compositions
WO2002045684A3 (en) Rapidly dispersing pharmaceutical composition comprising effervescent agents
CA2274910A1 (en) Flat medicament preparation for the application and release of buprenorphine or a pharmacologically comparable substance in the buccal cavity, and method of producing the same
CA2087146A1 (en) Flavour-masked pharmaceutical compositions
MXPA02003596A (en) Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation.
DE69519685D1 (en) ORAL MEDICINAL PRODUCT WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES
NZ501950A (en) Medicinal compositions for application to mucosa
AU3345197A (en) Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
WO2002017855A3 (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
WO2002045686A3 (en) Pharmaceutical paste comprising an acid-labile active ingredient
HUP0105481A2 (en) Pharmaceutical compositions containing clarithromycin and process for their preparation and their use
WO2003018064A3 (en) Lipophilic drug compositions
WO1999043299A3 (en) Oral formulation for hydrophilic drugs
CA2285985A1 (en) A method for preparing aqueous liposomal compositions comprising an active ingredient which is highly insoluble in water

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase